Abstract
The combination of genetic background together with food excess and lack of exercise has become the cornerstone of metabolic disorders associated to lifestyle. The scenario is furthermore reinforced by their interaction with other environmental factors (stress, sleeping patterns, education, culture, rural versus urban locations, and xenobiotics, among others) inducing epigenetic changes in the exposed individuals. The immediate consequence is the development of further alterations like obesity and metabolic syndrome, and other adverse health conditions (type-2 diabetes, cardiovascular diseases, cancer, reproductive, immune and neurological disorders). Thus, having in mind the impact of the metabolic syndrome on the worldwide public health, the present review affords the relative roles and the interrelationships of nature (genetic predisposition to metabolic syndrome) and nurture (lifestyle and environmental effects causing epigenetic changes), on the establishment of the metabolic disorders in women; disorders that may evolve to metabolic syndrome prior or during pregnancy and may be transmitted to their descendants.
Keywords: Developmental-programming, endocrine-disrupting-chemicals, epigenetics, lifestyle, metabolic-syndrome, nutrition, obesogenics, transgenerational-programming.
Current Pharmaceutical Biotechnology
Title:Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Volume: 17 Issue: 7
Author(s): Antonio Gonzalez-Bulnes, Susana Astiz, Cristina Ovilo, Consolacion Garcia-Contreras and Marta Vazquez-Gomez
Affiliation:
Keywords: Developmental-programming, endocrine-disrupting-chemicals, epigenetics, lifestyle, metabolic-syndrome, nutrition, obesogenics, transgenerational-programming.
Abstract: The combination of genetic background together with food excess and lack of exercise has become the cornerstone of metabolic disorders associated to lifestyle. The scenario is furthermore reinforced by their interaction with other environmental factors (stress, sleeping patterns, education, culture, rural versus urban locations, and xenobiotics, among others) inducing epigenetic changes in the exposed individuals. The immediate consequence is the development of further alterations like obesity and metabolic syndrome, and other adverse health conditions (type-2 diabetes, cardiovascular diseases, cancer, reproductive, immune and neurological disorders). Thus, having in mind the impact of the metabolic syndrome on the worldwide public health, the present review affords the relative roles and the interrelationships of nature (genetic predisposition to metabolic syndrome) and nurture (lifestyle and environmental effects causing epigenetic changes), on the establishment of the metabolic disorders in women; disorders that may evolve to metabolic syndrome prior or during pregnancy and may be transmitted to their descendants.
Export Options
About this article
Cite this article as:
Gonzalez-Bulnes Antonio, Astiz Susana, Ovilo Cristina, Garcia-Contreras Consolacion and Vazquez-Gomez Marta, Nature and Nurture in the Early-Life Origins of Metabolic Syndrome, Current Pharmaceutical Biotechnology 2016; 17 (7) . https://dx.doi.org/10.2174/1389201017666160301103835
DOI https://dx.doi.org/10.2174/1389201017666160301103835 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug-Induced Hypokalaemia
Current Drug Safety Conference Report: 9th International Summer School of Neurology
CNS & Neurological Disorders - Drug Targets Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Current Pharmaceutical Design New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Proteomics to Unravel Platelet-Related Diseases and Identify Novel Anti-Platelet Drugs
Current Medicinal Chemistry Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Imbalance Between Leukotriene Synthesis and Catabolism Contributes to the Pathogenesis of Allergic Diseases
Medicinal Chemistry Towards Prevention of Ovarian Cancer
Current Cancer Drug Targets Nitroxyl Anion Mediates Relaxation in Mesenteric Arteries from Angiotensin II Hypertensive Mice
Current Vascular Pharmacology Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews Markers of Arrhythmogenic Risk in Hypertensive Subjects
Current Pharmaceutical Design Will Antirheumatic Treatment Improve Cardiovascular Outcomes in Patients with Rheumatoid Arthritis?
Current Pharmaceutical Design Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design